Loading clinical trials...
Loading clinical trials...
TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. It is hypothesized that regular tr...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04526665 · Primary Biliary Cirrhosis
NCT03301506 · Primary Biliary Cirrhosis
NCT03743272 · Liver Diseases, Primary Biliary Cirrhosis, and more
NCT02846896 · Primary Biliary Cirrhosis
NCT03112681 · Primary Biliary Cirrhosis
The first hospital of Jilin University
Changchun, Jilin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions